The Most Common AI Mistakes Pharmaceutical and Life Sciences Make

Researchers use these tools to predict protein folding, toxicity, or binding affinity but do not ask what compounds the model was trained on. If the model learned from historical failures in your specific target class, it will reproduce those blindspots.

The fix

Before using any prediction for decision making, request the training dataset composition and run a retrospective test on compounds your team already synthesised and tested.

When Insilico or BenevolentAI ranks candidate molecules by predicted potency and selectivity, teams move to synthesis without asking whether the AI considered synthetic accessibility or off-target binding. The model may optimise only for the features you measured in training.

The fix

Always synthesise and test at least the top three AI-ranked candidates in parallel, not sequentially, to catch predictions that fail in reality.

Large language models hallucinate citations and conflate similar compounds. A chatbot summary of antagonist potency across papers can mix up IC50 values or miss crucial structural differences that change mechanism.

The fix

Assign one senior medicinal chemist to read the original papers and flag any discrepancies in the AI-generated summary before the team acts on it.

Schrödinger models trained on human protein structures may not accurately predict binding to rodent homologues with different loop conformations. Teams move straight to animal studies based on AI scores and waste time on compounds that do not work in vivo.

The fix

Run parallel in vitro assays against both human and your chosen animal species target before committing to animal efficacy studies.

BenevolentAI or similar tools recommend novel scaffolds based on statistical correlation, not mechanistic understanding. Your team may adopt a scaffold that failed for a reason the AI never saw in its training data.

The fix

After each failed scaffold, document the actual failure mode (clearance, toxicity, aggregation, off-target) and store it separately from your AI training data so future searches can account for it.

When IBM Watson or internal AI tools suggest a trial endpoint based on historical data, they optimise for statistical power or recruitment speed, not patient relevance. Your trial might hit its primary endpoint and still miss what regulators or patients care about.

The fix

For any AI-recommended primary or secondary endpoint, compare it against your target patient population's stated priorities from published qualitative research or patient advisory boards.

AI tools analyse historical trials and flag endpoints with high variance as hard to achieve. Teams drop those endpoints from their protocol, eliminating measures that actually matter to patients even if the statistical lift is steeper.

The fix

Keep patient-relevant endpoints in your trial design even if AI rates them as underpowered; increase sample size or run a separate sub-study rather than abandoning them.

Machine learning models trained on recruitment success will recommend tight inclusion criteria to maximise enrolment speed. These criteria often exclude elderly patients, those with comorbidities, or ethnic groups underrepresented in your training data.

The fix

After AI-generated inclusion criteria, conduct a feasibility check: estimate how many patients in your target market would actually qualify, then broaden criteria if the number is unrealistically small.

Unsupervised clustering by AI finds statistical subgroups in your trial data, but those subgroups may not correspond to clinically meaningful disease subtypes. You may file for approval claiming a responder population that regulators cannot understand or reproduce.

The fix

Before proposing any AI-identified subgroup analysis in your regulatory dossier, validate it in independent published cohorts or pre-specify the biological mechanism that explains the subgroup difference.

AI models rank endpoints by predicted effect size or historical success rate. They do not know that a small effect on a patient-reported outcome may matter more to regulators than a large effect on a biomarker that does not correlate with how patients feel.

The fix

Before finalising any trial endpoint list, present both the AI-ranked priorities and clinical rationale to at least two independent clinicians who treat the disease and ask them to object in writing.

When you use ChatGPT, Insilico, or internal AI to generate comparative efficacy narratives or data summaries for your regulatory dossier, regulators see the polished output but not the model's uncertainty or the data it excludes. Hidden weaknesses become apparent only after approval.

The fix

Create a separate technical summary documenting which analyses were AI-assisted, what data the AI saw, and what validation you performed before including any AI-generated content in your submission.

Insilico or IBM Watson can predict plasma clearance from structure, but your drug may behave differently in elderly patients, those with renal disease, or those on interacting medicines. Regulators will ask for clinical PK data anyway and will not accept model predictions as a substitute.

The fix

Use AI PK predictions only to inform which populations or drug-drug interactions to test clinically; plan clinical PK studies before submission, not after.

Large language models cite papers that do not exist or misrepresent competitor trial results. If your competitive analysis or market assessment in a regulatory briefing contains hallucinated citations, regulators will lose confidence in your data integrity.

The fix

For any competitive claim or competitor trial result mentioned in your regulatory strategy or dossier, retrieve and read the original publication yourself before using it.

AI tools can summarise adverse event data by frequency and severity, but they do not understand causation, severity grading, or why a safety signal matters. A chatbot-drafted safety narrative may claim an event is unrelated to your drug when regulators think it clearly is.

The fix

Have your head of clinical safety or principal investigator independently review and approve all safety analysis language before it enters your regulatory dossier.

BenevolentAI or internal tools may suggest efficient post-approval study designs, but they optimise for logistics, not for what regulators in your target geographies actually expect to see. You file a study plan that does not address regulator concerns.

The fix

Before proposing any post-approval study, schedule a pre-submission meeting with the relevant regulatory agency and ask explicitly what evidence they need; only then design your study.